GPCR-targeting nanobodies: Attractive research tools, diagnostics, and therapeutics

Trends in Pharmacological Sciences

Volumn 35, Issue 5, 2014, Pages 247-255

  Mujić Delić, Azra ^a   De Wit, Raymond H ^a   Verkaar, Folkert ^a   Smit, Martine J ^a  

^a AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

Author keywords

GPCRs; nanobodies; signaling; single domain antibody; VHH

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; G PROTEIN COUPLED RECEPTOR; NANOBODY;

ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; BINDING AFFINITY; BIOSENSOR; CRYSTALLIZATION; DIAGNOSTIC VALUE; HEAVY CHAIN; IMMUNOGENICITY; MOLECULAR IMAGING; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

GPCRS; NANOBODIES; SIGNALING; SINGLE-DOMAIN ANTIBODY; VHH;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED; SINGLE-DOMAIN ANTIBODIES;

EID: 84899649324     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.03.003     Document Type: Review

References (98)

1. S. Rajagopal et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors Nat. Rev. Drug Discov. 9 2010 373 386
2. J.P. Overington et al. How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
3. C.J. Hutchings et al. Therapeutic antibodies directed at G protein-coupled receptors MAbs 2 2010 594 606
4. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
5. A. Beck, and J.M. Reichert Marketing approval of mogamulizumab: a triumph for glyco-engineering MAbs 4 2012 419 425
6. A. Klarenbeek et al. Targeting chemokines and chemokine receptors with antibodies Drug Discov. Today Technol. 9 2012 e237 e244
7. D.R. Webb et al. Opportunities for functional selectivity in GPCR antibodies Biochem. Pharmacol. 85 2013 147 152
8. C. Hamers-Casterman et al. Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
9. A.S. Greenberg et al. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks Nature 374 1995 168 173
10. K.E. Conrath et al. Emergence and evolution of functional heavy-chain antibodies in Camelidae Dev. Comp. Immunol. 27 2003 87 103
11. M.F. Flajnik et al. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol. 9 2011 e1001120
12. A. Frenzel et al. Expression of recombinant antibodies Front. Immunol. 4 2013 217
13. M. Arbabi-Ghahroudi et al. Prokaryotic expression of antibodies Cancer Metastasis Rev. 24 2005 501 519
14. M.M. Harmsen, and H.J. De Haard Properties, production, and applications of camelid single-domain antibody fragments Appl. Microbiol. Biotechnol. 77 2007 13 22
15. S. Muyldermans Nanobodies: natural single-domain antibodies Annu. Rev. Biochem. 82 2013 775 797
16. M. Dumoulin et al. Single-domain antibody fragments with high conformational stability Protein Sci. 11 2002 500 515
17. S. Ewert et al. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains Biochemistry 41 2002 3628 3636
18. M.M. Harmsen et al. Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy Appl. Microbiol. Biotechnol. 72 2006 544 551
19. S. Jahnichen et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells Proc. Natl. Acad. Sci. U.S.A. 107 2010 20565 20570
20. D. Maussang et al. Llama-derived single variable domains (nanobodies) directed against CXCR7 reduce head and neck cancer cell growth in vivo J. Biol. Chem. 288 2013 29562 29572
21. K.R. Schmitz et al. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains Structure 21 2013 1214 1224
22. E. De Genst et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies Proc. Natl. Acad. Sci. U.S.A. 103 2006 4586 4591
23. V. Cortez-Retamozo et al. Efficient cancer therapy with a nanobody-based conjugate Cancer Res. 64 2004 2853 2857
24. R.A. Harrison et al. Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera Toxicon 47 2006 364 368
25. K. Movahedi et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages Cancer Res. 72 2012 4165 4177
26. B.M. Tijink et al. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology Mol. Cancer Ther. 7 2008 2288 2297
27. K. Coppieters et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis Arthritis Rheum. 54 2006 1856 1866
28. M.J. Vosjan et al. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy Mol. Cancer Ther. 11 2012 1017 1025
29. ® - a new potential drug in multiple myeloma treatment Eur. J. Haematol. 91 2013 399 410
30. J.A. Kolkman, and D.A. Law Nanobodies - from llamas to therapeutic proteins Drug Discov. Today Technol. 7 2010 e95 e146
31. C. Xavier et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer J. Nucl. Med. 54 2013 776 784
32. I. Vaneycken et al. Immuno-imaging using nanobodies Curr. Opin. Biotechnol. 22 2011 877 881
33. S. Oliveira et al. Targeting tumors with nanobodies for cancer imaging and therapy J. Control. Release 172 2013 607 617
34. A.M. Cuesta et al. Multivalent antibodies: when design surpasses evolution Trends Biotechnol. 28 2010 355 362
35. I. Vaneycken et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer FASEB J. 25 2011 2433 2446
36. M.J. Vosjan et al. Facile labelling of an anti-epidermal growth factor receptor nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET Eur. J. Nucl. Med. Mol. Imaging 38 2011 753 763
37. S. Put et al. SPECT imaging of joint inflammation with nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis J. Nucl. Med. 54 2013 807 814
38. A. Broisat et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions Circ. Res. 110 2012 927 937
39. T. Li et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging FASEB J. 26 2012 3969 3979
40. K.S. Rutgers et al. Transmigration of β amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier Neuroscience 190 2011 37 42
41. A.S. Haqqani et al. Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method Mol. Pharm. 10 2012 1542 1556
42. T. Mima, and N. Nishimoto Clinical value of blocking IL-6 receptor Curr. Opin. Rheumatol. 21 2009 224 230
43. R.C. Roovers et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth Int. J. Cancer 129 2011 2013 2024
44. M. Behdani et al. Generation and characterization of a functional nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor Mol. Immunol. 50 2012 35 41
45. S.A. Sarker et al. Anti-rotavirus protein reduces stool output in infants with diarrhea: a randomized placebo-controlled trial Gastroenterology 145 2013 740 748
46. C. Vincke et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold J. Biol. Chem. 284 2009 3273 3284
47. D.J. Scholten et al. Pharmacological modulation of chemokine receptor function Br. J. Pharmacol. 165 2012 1617 1643
48. A. Chatterjee et al. Chemokines and chemokine receptors in susceptibility to HIV-1 infection and progression to AIDS Dis. Markers 32 2012 143 151
49. J. Vandercappellen et al. The role of CXC chemokines and their receptors in cancer Cancer Lett. 267 2008 226 244
50. G.E. White et al. CC chemokine receptors and chronic inflammation -therapeutic opportunities and pharmacological challenges Pharmacol. Rev. 65 2013 47 89
51. C.M. Perry Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection Drugs 70 2010 1189 1213
52. J.F. DiPersio et al. Plerixafor Nat. Rev. Drug Discov. 8 2009 105 106
53. B. Furusato et al. CXCR4 and cancer Pathol. Int. 60 2010 497 505
54. R.A. Weiss Gulliver's travels in HIVland Nature 410 2001 963 967
55. A. Zlotnik et al. Homeostatic chemokine receptors and organ-specific metastasis Nat. Rev. Immunol. 11 2011 597 606
56. D.G. Duda et al. CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 17 2011 2074 2080
57. J.M. Burns et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development J. Exp. Med. 203 2006 2201 2213
58. S. Rajagopal et al. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7 Proc. Natl. Acad. Sci. U.S.A. 107 2010 628 632
59. C. Blanchetot et al. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function J. Biol. Chem. 288 2013 25173 25182
60. M.J. Craig, and R.D. Loberg CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases Cancer Metastasis Rev. 25 2006 611 619
61. S.J. Allen et al. Chemokine: receptor structure, interactions, and antagonism Annu. Rev. Immunol. 25 2007 787 820
62. A.E. Koch et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis J. Clin. Invest. 90 1992 772 779
63. S. Qin et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions J. Clin. Invest. 101 1998 746 754
64. D.J. Mahad, and R.M. Ransohoff The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) Semin. Immunol. 15 2003 23 32
65. T.L. Sorensen et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients J. Clin. Invest. 103 1999 807 815
66. S.G. Rasmussen et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor Nature 450 2007 383 387
67. T. Warne et al. Structure of a β1-adrenergic G-protein-coupled receptor Nature 454 2008 486 491
68. T. Shimamura et al. Structure of the human histamine H1 receptor complex with doxepin Nature 475 2011 65 70
69. K. Hollenstein et al. Structure of class B GPCR corticotropin-releasing factor receptor 1 Nature 499 2013 438 443
70. J. Steyaert, and B.K. Kobilka Nanobody stabilization of G protein-coupled receptor conformational states Curr. Opin. Struct. Biol. 21 2011 567 572
71. S. Koide Engineering of recombinant crystallization chaperones Curr. Opin. Struct. Biol. 19 2009 449 457
72. 2 adrenoceptor Nature 469 2011 175 180
73. A.C. Kruse et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 504 2013 101 106
74. S.G. Rasmussen et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex Nature 477 2011 549 555
75. J. Ries et al. A simple, versatile method for GFP-based super-resolution microscopy via nanobodies Nat. Methods 9 2012 582 584
76. U. Rothbauer et al. Targeting and tracing antigens in live cells with fluorescent nanobodies Nat. Methods 3 2006 887 889
77. R. Irannejad et al. Conformational biosensors reveal GPCR signalling from endosomes Nature 495 2013 534 538
78. G.H. Westfield et al. Structural flexibility of the Gαs α-helical domain in the β2-adrenoceptor Gs complex Proc. Natl. Acad. Sci. U.S.A. 108 2011 16086 16091
79. S. Ferrandon et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis Nat. Chem. Biol. 5 2009 734 742
80. D. Calebiro et al. Imaging of persistent cAMP signaling by internalized G protein-coupled receptors J. Mol. Endocrinol. 45 2010 1 8
81. F. Mullershausen et al. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors Nat. Chem. Biol. 5 2009 428 434
82. D.P. Staus et al. Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies Mol. Pharmacol. 85 2014 472 481
83. R. Panetta, and M.T. Greenwood Physiological relevance of GPCR oligomerization and its impact on drug discovery Drug Discov. Today 13 2008 1059 1066
84. M. O'Hayre et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer Nat. Rev. Cancer 13 2013 412 424
85. T. Ishida et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study J. Clin. Oncol. 30 2012 837 842
86. A.J. George The antibody molecule Methods Mol. Med. 40 2000 1 21
87. A.C. Chan, and P.J. Carter Therapeutic antibodies for autoimmunity and inflammation Nat. Rev. Immunol. 10 2010 301 316
88. L. Sanz et al. Antibodies and gene therapy: teaching old 'magic bullets' new tricks Trends Immunol. 25 2004 85 91
89. C. Chothia et al. Structural repertoire of the human VH segments J. Mol. Biol. 227 1992 799 817
90. K.B. Vu et al. Comparison of llama VH sequences from conventional and heavy chain antibodies Mol. Immunol. 34 1997 1121 1131
91. A. Mortier et al. Regulation of chemokine activity by posttranslational modification Pharmacol. Ther. 120 2008 197 217
92. J.J. Ziarek et al. Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction Curr. Top. Med. Chem. 12 2012 2727 2740
93. M. Hachet-Haas et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12 J. Biol. Chem. 283 2008 23189 23199
94. A.E. Proudfoot et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines Proc. Natl. Acad. Sci. U.S.A. 100 2003 1885 1890
95. J.J. Ziarek et al. Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus J. Biol. Chem. 288 2013 737 746
96. Z. Johnson et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system J. Immunol. 173 2004 5776 5785
97. I.C. Severin et al. Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans J. Biol. Chem. 285 2010 17713 17724
98. A. Nellen et al. Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury PLoS ONE 7 2012 e36614